創新藥物的商業成功之路 - 從實驗室到上市

This session explores the dynamic field of translational medicine, highlighting its journey from innovative research to commercial triumph. Delve into the critical elements and processes that bridge the gap between laboratory discoveries and marketable therapies. Case studies of recent breakthroughs will illustrate how novel scientific insights are transformed into commercially viable treatments, addressing unmet medical needs. Topics will include strategic partnerships, regulatory pathways, scalable manufacturing practices that ensure clinical efficacy and safety, and an examination of successful funding mechanisms. Attendees will gain valuable knowledge around navigating the complexities of translational medicine, and will learn how to effectively translate cutting-edge research into life-changing therapies, driving innovation and improving patient outcomes.
 

16:00 – 16:05

Opening Remarks

Huey-Kang Sytwu, President, National Health Research Institutes; Distinguished Investigator, National Institute of Infectious Diseases and Vaccinology, NHRI; Academician, Academia Sinica

16:05 – 16:25

Understanding Protein Dynamics for Structure-based Drug Design: Design Stories of Crizotinib, Lorlatinib and Repotrectinib

Jingrong Jean Cui, President & CEO, BlossomHill Therapeutics, Inc.
16:25 – 16:45

Bozitinib: from Bench to Bedside

Boyu Zhong, President, CSO, Tyligand Bioscience Ltd.
16:45 – 17:05

Translation Medicine from CMC perspectives, from Preclinical to Commercial

David Chang, Ph.D., CEO, Taiwan Bio-Manufacturing Corporation (TBMC)
17:05 – 17:30

Panel Discussion

Moderator:
Hsing-Pang Hsieh, Director, National Health Research Institutes, Institute of Biotechnology and Pharmaceutical Research (IBPR)

Panelists:

• Jingrong Jean Cui, President & CEO, BlossomHill Therapeutics, Inc.
• Boyu Zhong,President, CSO, Tyligand Bioscience Ltd.
• David Chang, Ph.D., CEO, Taiwan Bio-Manufacturing Corporation (TBMC)